Juventas Moves Into Phase II With Funds From $22M Series B
This article was originally published in The Pink Sheet Daily
Executive Summary
Cleveland Clinic spinout Juventas Therapeutics raised $22 million that will help fund mid-stage studies of its adult stem cell treatment.